Paul W. Manley

Dr. Paul W. Manley received his Ph.D. in Organic Chemistry from Liverpool University. He has over 35 years of medicinal chemistry experience in the pharmaceutical industry, across several therapeutic areas. Since year 2000, he has been engaged in the discovery and development of drugs targeting protein kinases. most notably nilotinib (Tasigna®), midostaurin (Rydapt®) and asciminib (Scemblix®), marketed for the treatment of leukaemias. He has led a number of international drug discovery teams, including collaborations with third parties. In addition to his drug discovery responsibilities, he is research representative on the Tasigna, Rydapt, Scemblix and Glivec Global Project Teams, contributing to documentation prepared for Health Authorities (e.g. NDAs). He has co-authored over 130 scientific papers on leukaemia and oncology drugs, medicinal and organic chemistry, and is co-inventor of over 70 patents. He received a Novartis Leading Scientist award in 2007, in 2012 was honoured by American Chemical Society as a Hero of Chemistry, in 2013 was a recipient of the Edison Patent award and in 2018 was awarded SISF-SCS 2018 Distinguished Investigator Award from the Swiss Chemical Society.